The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index; 11 of the 38 sources its claims cite were checked for support.
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas
Open accessPublished version of a preprint
Abstract
PURPOSE: p53 pathway alterations are key molecular events in glioblastoma (GBM). MDM2 inhibitors increase expression and stability of p53 and are presumed to be most efficacious in patients with TP53 wild-type and MDM2-amplified cancers. However, this biomarker hypothesis has not been tested in patients or patient-derived models for GBM. EXPERIMENTAL DESIGN: We performed a preclinical evaluation of RG7112 MDM2 inhibitor, across a panel of 36 patient-derived GBM cell lines (PDCL), each genetically characterized according to their P53 pathway status. We then performed a pharmacokinetic (PK) profiling of RG7112 distribution in mice and evaluated the therapeutic activity of RG7112 in orthotopic and subcutaneous GBM models. RESULTS: MDM2-amplified PDCLs were 44 times more sensitive than TP53-mutated lines that showed complete resistance at therapeutically attainable concentrations (avg. IC50 of 0.52 μmol/L vs. 21.9 μmol/L). MDM4-amplified PDCLs were highly sensitive but showed intermediate response (avg. IC50 of 1.2 μmol/L), whereas response was heterogeneous in TP53 wild-type PDCLs with normal MDM2/4 levels (avg. IC50 of 7.7 μmol/L). In MDM2-amplified lines, RG7112 restored p53 activity inducing robust p21 expression and apoptosis. PK profiling of RG7112-treated PDCL intracranial xenografts demonstrated that the compound significantly crosses the blood-brain and the blood-tumor barriers. Most importantly, treatment of MDM2-amplified/TP53 wild-type PDCL-derived model (subcutaneous and orthotopic) reduced tumor growth, was cytotoxic, and significantly increased survival. CONCLUSIONS: These data strongly support development of MDM2 inhibitors for clinical testing in MDM2-amplified GBM patients. Moreover, significant efficacy in a subset of non-MDM2-amplified models suggests that additional markers of response to MDM2 inhibitors must be identified.
Overview
CoChat Summary
TL;DR
RG7112, an MDM2 inhibitor, was tested across 36 patient-derived glioblastoma cell lines and mouse models; MDM2-amplified/TP53 wild-type lines were most sensitive, and orthotopic treatment increased survival. The data support clinical testing in MDM2-amplified GBM while indicating that additional response markers are needed.
Key findings
- MDM2-amplified PDCLs were 44 times more sensitive than TP53-mutated lines at therapeutically attainable concentrations (average IC50 0.52 μM vs 21.9 μM); MDM4-amplified PDCLs had intermediate sensitivity (average IC50 1.2 μM), and TP53 wild-type PDCLs with normal MDM2/4 levels were heterogeneous (average IC50 7.7 μM).
- In MDM2-amplified lines, RG7112 restored p53 activity, induced p21 expression and apoptosis; PK profiling in intracranial xenografts showed tumor-hemisphere Cmax of 3328 ng/g (4.8 μM) and contralateral-hemisphere Cmax of 2025 ng/g (2.9 μM), both above the 0.5 μM in vitro IC50, with brain-to-plasma AUC ratio 0.198 in tumor vs 0.106 in contralateral brain (1.9-fold greater).
- In vivo, subcutaneous 3731 MDM2-amplified tumors showed complete growth suppression and 80% regression during 21 days of treatment (p=0.003), with rapid regrowth after withdrawal; orthotopic tumor volume decreased from 4.91 mm3 to 4.28 mm3 (13% decrease) vs vehicle increase from 5.97 to 84.84 mm3 (14.2-fold), and RG7112 prolonged survival (p=0.0003), with a 50% increase in median survival.
- MDM2 amplification did not affect prognosis: 43/696 (6.2%) newly diagnosed GBM were MDM2-amplified, with median overall survival 15.5 months in both amplified and non-amplified groups; MDM2 amplification and TP53 status were maintained at recurrence.
Methods
- Preclinical evaluation across 36 GBM cell lines, including 32 patient-derived cell lines from two cohorts plus 4 commercial lines, genetically characterized for TP53, MDM2 and MDM4 status; RG7112 sensitivity was measured by 72-hour proliferation assays with IC50 determination.
- In vivo studies used orthotopic (luciferase-labeled, intracranial) and subcutaneous GBM xenografts in nude mice; RG7112 was given by oral gavage at 100 mg/kg once daily, 5 days/week for 3 weeks, with bioluminescence, MRI, survival, and pharmacodynamic analyses.
- Pharmacokinetics measured RG7112 in plasma, brain hemispheres and subcutaneous tumors by LC-MS/MS; statistical analyses included ANOVA/Tukey, t-tests, Kaplan-Meier/log-rank tests, and non-compartmental PK analysis with the Bailer method for destructive sampling.
Limitations
- Stated: destructive PK sampling meant variability for parameters other than AUC0-t could not be determined and no statistical tests were performed on those parameters; intravascular drug/blood contribution to brain AUCs could not be excluded because GBM vasculature includes poorly perfused vessels; orthotopic tumor marker changes after 3 weeks were not statistically significant; resistance mechanisms remain unclear, and TP53 sequencing of recurrent tumors did not detect mutations; MDM4 findings require confirmation in additional cell lines; additional predictive markers are needed.
- Evident: only 2/32 PDCLs had MDM2 high-level amplification, limiting generalizability; efficacy was greater in subcutaneous than orthotopic models, likely due to higher drug exposure; all efficacy data are preclinical, with no clinical trial results reported here.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 2 Not valid · 18 Not checked · 115 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
§ Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas > Discussion
What the sources say
- Not checked — no full text of the sourcecites [29] Patton, 2006, Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3, Cancer Res source
- Not checked — no full text of the sourcecites [30] Wade, 2006, Hdmx modulates the outcome of p53 activation in human tumor cells, J Biol Chem source
- Could not verifycites [31] Vu, 2013, Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development, ACS Med Chem Lett sourceExperimental — accuracy not yet measured
The supplied cell-viability passage (section labeled Abstract; page unavailable) compares responses by p53 mutation status, not MDM4 amplification. Searches for MDM4 amplification and MDMX-related Nutlin-3 resistance found no passage in our copy addressing whether MDM4 amplification reduces sensitivity. (LLM, conf=0.77)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Deregulation of the core p53 pathway occurs in 43% of cases due to: (i) TP53 gene mutation or homozygous deletion in 27.9% of cases, (ii) focal MDM2 amplification in 8–9% of cases, and (iii) focal MDM4 amplification in 7–9% of cases.”
§ Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas > Introduction
What the sources say
- Partly supportedcites [4] Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell sourceExperimental — accuracy not yet measured
In Results, ‘The landscape of somatic alterations in glioblastoma’ (page unavailable), the paper reports TP53 mutation/deletion in 27.9% of tumors and MDM1/2/4 amplification in 15.1%. Those figures total approximately 43%, but the paper reports 85.3% dysregulation of the p53 pathway when CDKN2A deletion is included. It does not give the cited separate 8–9% amplification rates for MDM2 and MDM4. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Deregulation of the core p53 pathway occurs in 43% of cases due to: (i) TP53 gene mutation or homozygous deletion in 27.9% of cases, (ii) focal MDM2 amplification in 8–9% of cases, and (iii) focal MDM4 amplification in 7–9% of cases.”
§ Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas > Introduction
What the sources say
- Partly supportedcites [4] Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell sourceExperimental — accuracy not yet measured
The Results sections on genomic gains and losses and on somatic alterations report MDM2 amplification in GBM. However, the only percentage given is 15.1% for amplification of MDM1, MDM2, or MDM4 combined; our copy does not give an 8–9% frequency for focal MDM2 amplification alone. (LLM, conf=0.87)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Deregulation of the core p53 pathway occurs in 43% of cases due to: (i) TP53 gene mutation or homozygous deletion in 27.9% of cases, (ii) focal MDM2 amplification in 8–9% of cases, and (iii) focal MDM4 amplification in 7–9% of cases.”
§ Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas > Introduction
What the sources say
- Partly supportedcites [4] Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell sourceExperimental — accuracy not yet measured
In Results, ‘The landscape of somatic alterations in glioblastoma’ (page not provided), the paper reports TP53 mutation or deletion in 27.9% of tumors. It does not specify that the deletions counted in that figure were homozygous, so the claim’s narrower deletion type is not established by our copy. (LLM, conf=0.82)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Live cardiac puncture exsanguination was shown to remove most of the blood and intravascular drug from functional vessels, suggesting that perfusion prior to brain harvesting has limited impact on PK measurements [16].”
§ Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas > Material and methods > Pharmacokinetics studies
What the sources say
- Partly supportedcites [16] Friden, 2010, Improved measurement of drug exposure in the brain using drug-specific correction for residual blood, J Cereb Blood Flow Metab sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that severing the heart before brain removal lowers measured vascular-space volumes because blood drains from the tissue. It does not establish that most blood or intravascular drug is removed, or assess whether perfusion has limited impact on PK measurements. The Introduction and Discussion instead emphasize that residual intravascular drug can substantially affect measured brain concentrations and requires correction. (LLM, conf=0.85)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims · 1 with their cited sources checked
Create a free account to see all 144 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 30
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple MDM2 inhibitors have significant efficacy in GBM preclinical models (7, 8, 10, 11) and have entered early-phase clinical trials in GBM.”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The MDM2 gene is amplified in approximately 7%–13% of GBM tumors”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [46]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Verreault et al. demonstrated that GBM tumors with MDM2 amplification are highly responsive to MDM2 inhibition.46”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Several MDM2 inhibitors have shown efficacy in GBM preclinical models, including SAR405838 (7), RG7112 (8), idasanutlin (RG7388; ref. 9)”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In MDM2-amplified cell lines, RG7112 restored p53 activity, crossed the blood–brain and the blood–tumor barrier and treatment of MDM2-amplified TP53 wild-type xenografts with the inhibitor reduced tumor growth and increased animal survival [117].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [117]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MDM2-amplified PDCLs were 44 times more sensitive than TP53 mutated lines that showed complete resistance at therapeutically attainable concentrations (avg. IC50 of 0.52 μM vs 21.9 μM).”
§ Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas > Abstract > Results
Reported 44 · recomputed 42.115385
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J. A., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,220
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
DNA damage-induced cell death by apoptosis
Roos, W. P., & Kaina, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.007 · Cited by 1,500
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
Cited by
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Glioblastoma targeted therapy: updated approaches from recent biological insights
Touat, M., Idbaih, A., Sanson, M., & Ligon, K. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx106 · Cited by 441
Self-citationRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets
Taylor, O. G., Brzozowski, J. S., & Skelding, K. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00963 · Cited by 322
Metadata
- Authors
- Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., Ligon, A. H., Mokhtari, K., Hoang-Xuan, K., Sanson, M., Alexander, B. M., Wen, P. Y., Delattre, J.-Y., Ligon, K. L., & Idbaih, A.
- Affiliations
- 1Inserm, U 1127, Paris, France.
- Centre National de la Recherche Scientifique (FR)
- Hôpital Saint-Louis (FR)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Center for Neuro-Oncology (US)
- Corresponding author
- Ligon, Keith L.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2016-02-29
- Volume
- 22
- Issue
- 5
- Pages
- 1185-1196
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4842012
- OpenAlex
- W1941304965
- Cited by
- 114
- References
- 48
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 8 · 2020: 14 · 2019: 11 · 2018: 10 · 2017: 7 · 2016: 8
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P01CA142536, R01CA170592, R01CA188228, P50CA165962)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- RG7112, MDM2 inhibitors, glioblastoma, MDM2 amplification, wild-type p53, p53 pathway, pharmacokinetics, blood-brain barrier penetration, orthotopic xenograft, subcutaneous xenograft, p21 expression, apoptosis, predictive biomarkers
- MeSH terms
- Animals, Glioblastoma, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Imidazolines, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-1015
- The paper
- Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., Ligon, A. H., Mokhtari, K., Hoang-Xuan, K., Sanson, M., Alexander, B. M., Wen, P. Y., Delattre, J.-Y., Ligon, K. L., & Idbaih, A. (2016). Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-1015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.